JP2013504554A - ムチン分泌を抑制するためのグアイフェネシンの使用 - Google Patents

ムチン分泌を抑制するためのグアイフェネシンの使用 Download PDF

Info

Publication number
JP2013504554A
JP2013504554A JP2012528455A JP2012528455A JP2013504554A JP 2013504554 A JP2013504554 A JP 2013504554A JP 2012528455 A JP2012528455 A JP 2012528455A JP 2012528455 A JP2012528455 A JP 2012528455A JP 2013504554 A JP2013504554 A JP 2013504554A
Authority
JP
Japan
Prior art keywords
composition
guaifenesin
administering
effective amount
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012528455A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013504554A5 (https=
Inventor
ヘルムート アルブレヒト
ケー チャル キム
ジェーンクレア シーグレーブ
ブルース ケー ルービン
ゲール ソロモン
Original Assignee
レキット ベンキサー エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/558,517 external-priority patent/US20110065744A1/en
Priority claimed from GBGB1002039.4A external-priority patent/GB201002039D0/en
Application filed by レキット ベンキサー エルエルシー filed Critical レキット ベンキサー エルエルシー
Publication of JP2013504554A publication Critical patent/JP2013504554A/ja
Publication of JP2013504554A5 publication Critical patent/JP2013504554A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012528455A 2009-09-12 2010-09-13 ムチン分泌を抑制するためのグアイフェネシンの使用 Pending JP2013504554A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12/558,517 US20110065744A1 (en) 2009-09-12 2009-09-12 Method Of Inhibiting Mucin Secretion
US12/558,517 2009-09-12
GBGB1002039.4A GB201002039D0 (en) 2010-02-09 2010-02-09 Method of inhibiting mucin secretion
GB1002039.4 2010-02-09
PCT/GB2010/051525 WO2011030163A1 (en) 2009-09-12 2010-09-13 Use of guaifenesin for inhibiting mucin secretion

Publications (2)

Publication Number Publication Date
JP2013504554A true JP2013504554A (ja) 2013-02-07
JP2013504554A5 JP2013504554A5 (https=) 2013-10-31

Family

ID=42941393

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012528455A Pending JP2013504554A (ja) 2009-09-12 2010-09-13 ムチン分泌を抑制するためのグアイフェネシンの使用

Country Status (12)

Country Link
EP (1) EP2475360A1 (https=)
JP (1) JP2013504554A (https=)
KR (1) KR20120068889A (https=)
CN (1) CN102596189A (https=)
AU (1) AU2010294008B2 (https=)
BR (1) BR112012005517A2 (https=)
CA (1) CA2773611A1 (https=)
MX (1) MX2012003042A (https=)
MY (1) MY161187A (https=)
RU (1) RU2012114323A (https=)
WO (1) WO2011030163A1 (https=)
ZA (1) ZA201201822B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150065539A1 (en) * 2012-04-06 2015-03-05 The Uab Research Foundation Methods for Increasing CFTR Activity
KR102211605B1 (ko) * 2018-02-26 2021-02-04 대한민국 개구리 배아를 이용한 기도 뮤신 분비 억제제의 스크리닝 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004503599A (ja) * 2000-07-14 2004-02-05 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア Ｅｇｆ−ｒアンタゴニストの投与による気道粘液産生の防止方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA963590B (en) * 1995-05-10 1996-11-19 Adcock Ingram Ltd Pharmaceutical composition
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US20040029864A1 (en) * 2002-02-04 2004-02-12 Pharmacia Corporation Treatment of colds and cough with a combination of a cyclooxygenase-2 selective inhibitor and a colds and cough active ingredient and compositions thereof
EP1633734A2 (en) * 2003-06-19 2006-03-15 Genaera Corporation Mucin synthesis inhibitors
US20050095288A1 (en) * 2003-11-03 2005-05-05 Andrx Labs, Llc Decongestant and expectorant tablets
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US20080014261A1 (en) * 2006-07-12 2008-01-17 Giordano John A Non-narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
US20090202633A1 (en) * 2008-01-03 2009-08-13 Siva Ramakrishna Velaga Extended release formulations of guaifenesin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004503599A (ja) * 2000-07-14 2004-02-05 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア Ｅｇｆ−ｒアンタゴニストの投与による気道粘液産生の防止方法

Also Published As

Publication number Publication date
MY161187A (en) 2017-04-14
EP2475360A1 (en) 2012-07-18
CA2773611A1 (en) 2011-03-17
AU2010294008A1 (en) 2012-04-05
BR112012005517A2 (pt) 2016-04-19
CN102596189A (zh) 2012-07-18
WO2011030163A1 (en) 2011-03-17
KR20120068889A (ko) 2012-06-27
ZA201201822B (en) 2013-05-29
AU2010294008B2 (en) 2014-08-14
MX2012003042A (es) 2012-05-29
RU2012114323A (ru) 2013-10-20

Similar Documents

Publication Publication Date Title
Ehre et al. An improved inhaled mucolytic to treat airway muco-obstructive diseases
Sermet-Gaudelus et al. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study
Zanasi et al. A reappraisal of the mucoactive activity and clinical efficacy of bromhexine
Wohlsen et al. Immediate allergic response in small airways
TW201902478A (zh) 治療肝臟疾病之方法
Chen et al. Reversal of chronic rhinosinusitis-associated sinonasal ciliary dysfunction
Lo Bello et al. Role of the mucins in pathogenesis of COPD: implications for therapy
Ailiyaer et al. A prospective trial of nebulized amikacin in the treatment of bronchiectasis exacerbation
Huang et al. High glucose disrupts autophagy lysosomal pathway in gingival epithelial cells via ATP6V0C
JP2013504554A (ja) ムチン分泌を抑制するためのグアイフェネシンの使用
US20200199103A1 (en) Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells
Zang et al. Protective effect of CD137 deficiency against postinfarction cardiac fibrosis and adverse cardiac remodeling by ERK1/2 signaling pathways
Garcia Cruz et al. Rhinosinusitis and Aspirin‐Exacerbated Respiratory Disease
Sindwani et al. Myospherulosis following sinus surgery: pathological curiosity or important clinical entity?
US20110065744A1 (en) Method Of Inhibiting Mucin Secretion
Huan The Chinese national guidelines on diagnosis and management of cough (December 2010)
Dundar et al. A safety investigation into topical effects of naproxen sodium on nasal epithelial cells and potential toxicity in local application
CN113181193A (zh) 卡泊三醇作为预防和治疗老年性骨质疏松的皮肤外用药的用途
EP1782808A1 (en) Preventive or therapeutic agent for chronic inflammatory lung disease
Takahashi et al. Effect of fudosteine, a cysteine derivative, on blood flow of tracheal microvasculature increased by airway inflammation
Ghanem et al. Apparent Yield Stress of Sputum as a Relevant Biomarker in Cystic Fibrosis. Cells 2021, 10, 3107
Shebani Ultrastructural Studies of the Airway Epithelium in Airway Diseases
CN115068492B (zh) 蒙花苷在制备预防或治疗肺纤维化的药物中的应用
JP2015509509A (ja) 慢性閉塞性疾患を治療するための医薬品組成物の製造のための、ルパタジンの使用
JP7328696B2 (ja) 角膜上皮細胞走化促進剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141204

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150107

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150624